Intellia Therapeutics, an asymmetric biotech opportunity?Intellia Therapeutics, Inc.BATS:NTLASwissquoteAn asymmetric investment strategy in the stock market consists of looking for opportunities where the potential upside is significantly greater than the accepted downside risk. It particularly targets innovative companies, undervalued businesses, or firms positioned on powerful structural trends, capable of generating substantial revaluation over several years. The goal is not to be right every time, but to build a portfolio where a few major successes can more than offset less successful investments. This approach requires patience, discipline, and effective risk management, but it allows investors to benefit from situations where the market still underestimates the future potential of an asset. Naturally, I would first like to make one important point clear: I am not providing investment advice today. You are free to make your own decisions. However, when searching for asymmetric investment strategies in the stock market, the healthcare sector can sometimes offer attractive long-term opportunities. These are sometimes highly speculative strategies, particularly in the sector I am going to discuss: listed biotechnology companies. And Intellia Therapeutics could potentially represent an interesting long-term investment strategy over the next few years, especially if the U.S. FDA approves this biotech’s treatments starting in 2027. Here is why. Founded in 2014, Intellia Therapeutics is a U.S. company specializing in gene editing based on CRISPR-Cas9 technology. This scientific revolution could potentially allow researchers to directly modify DNA in order to treat diseases that have until now been considered incurable. The stakes are enormous: moving from medicine that treats symptoms to medicine capable of correcting the root cause of a disease. Intellia’s main strength lies in its leading program targeting transthyretin amyloidosis, a rare genetic disease that can cause severe damage to the nervous system and the heart. Early clinical results have shown encouraging progress, increasing hopes for future commercialization if the next regulatory steps are successfully completed. The chart below shows the weekly Japanese candlesticks of Intellia Therapeutics stock. A long-term technical base has developed between $7 and $20. The market is currently heavily discounting the stock due to uncertainties surrounding clinical development, high research costs, and the inherent failure risk of biotechnology companies. This stock market pressure explains why some innovative biotech companies can sometimes offer an asymmetric profile: a depressed valuation today, but significant revaluation potential in the event of scientific and commercial success. Of course, the risk remains extremely high: an unfavorable FDA decision, insufficient clinical results, or financial difficulties could weigh heavily on the company. This is why such an investment should be considered a speculative position, limited in size within a diversified portfolio. However, for an investor capable of accepting high volatility, Intellia perfectly illustrates the logic of an asymmetric strategy: investing in a disruptive technology whose potential impact could be considerable if scientific results confirm expectations. The chart below complements the previous one by adding the lessons from the Ichimoku system on the weekly timeframe. The price would need to move back above the weekly cloud to provide the first bullish technical signal. DISCLAIMER: This content is intended for individuals who are familiar with financial markets and instruments and is for information purposes only. The presented idea (including market commentary, market data and observations) is not a work product of any research department of Swissquote or its affiliates. This material is intended to highlight market action and does not constitute investment, legal or tax advice. If you are a retail investor or lack experience in trading complex financial products, it is advisable to seek professional advice from licensed advisor before making any financial decisions. This content is not intended to manipulate the market or encourage any specific financial behavior. Swissquote makes no representation or warranty as to the quality, completeness, accuracy, comprehensiveness or non-infringement of such content. The views expressed are those of the consultant and are provided for educational purposes only. Any information provided relating to a product or market should not be construed as recommending an investment strategy or transaction. Past performance is not a guarantee of future results. Swissquote and its employees and representatives shall in no event be held liable for any damages or losses arising directly or indirectly from decisions made on the basis of this content. The use of any third-party brands or trademarks is for information only and does not imply endorsement by Swissquote, or that the trademark owner has authorised Swissquote to promote its products or services. Swissquote is the marketing brand for the activities of Swissquote Bank Ltd (Switzerland) regulated by FINMA, Swissquote Capital Markets Limited regulated by CySEC (Cyprus), Swissquote Bank Europe SA (Luxembourg) regulated by the CSSF, Swissquote Ltd (UK) regulated by the FCA, Swissquote Financial Services (Malta) Ltd regulated by the Malta Financial Services Authority, Swissquote MEA Ltd. (UAE) regulated by the Dubai Financial Services Authority, Swissquote Pte Ltd (Singapore) regulated by the Monetary Authority of Singapore, Swissquote Asia Limited (Hong Kong) licensed by the Hong Kong Securities and Futures Commission (SFC) and Swissquote South Africa (Pty) Ltd supervised by the FSCA. Products and services of Swissquote are only intended for those permitted to receive them under local law. All investments carry a degree of risk. The risk of loss in trading or holding financial instruments can be substantial. The value of financial instruments, including but not limited to stocks, bonds, cryptocurrencies, and other assets, can fluctuate both upwards and downwards. There is a significant risk of financial loss when buying, selling, holding, staking, or investing in these instruments. SQBE makes no recommendations regarding any specific investment, transaction, or the use of any particular investment strategy. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The vast majority of retail client accounts suffer capital losses when trading in CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Digital Assets are unregulated in most countries and consumer protection rules may not apply. As highly volatile speculative investments, Digital Assets are not suitable for investors without a high-risk tolerance. Make sure you understand each Digital Asset before you trade. Cryptocurrencies are not considered legal tender in some jurisdictions and are subject to regulatory uncertainties. The use of Internet-based systems can involve high risks, including, but not limited to, fraud, cyber-attacks, network and communication failures, as well as identity theft and phishing attacks related to crypto-assets.